1. Home
  2. CYTK vs ALE Comparison

CYTK vs ALE Comparison

Compare CYTK & ALE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • ALE
  • Stock Information
  • Founded
  • CYTK 1997
  • ALE 1906
  • Country
  • CYTK United States
  • ALE United States
  • Employees
  • CYTK N/A
  • ALE N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • ALE Power Generation
  • Sector
  • CYTK Health Care
  • ALE Utilities
  • Exchange
  • CYTK Nasdaq
  • ALE Nasdaq
  • Market Cap
  • CYTK 4.6B
  • ALE 3.8B
  • IPO Year
  • CYTK 2004
  • ALE N/A
  • Fundamental
  • Price
  • CYTK $35.39
  • ALE $64.25
  • Analyst Decision
  • CYTK Buy
  • ALE
  • Analyst Count
  • CYTK 13
  • ALE 0
  • Target Price
  • CYTK $71.58
  • ALE N/A
  • AVG Volume (30 Days)
  • CYTK 1.7M
  • ALE 603.1K
  • Earning Date
  • CYTK 08-07-2025
  • ALE 08-07-2025
  • Dividend Yield
  • CYTK N/A
  • ALE 4.55%
  • EPS Growth
  • CYTK N/A
  • ALE N/A
  • EPS
  • CYTK N/A
  • ALE 3.17
  • Revenue
  • CYTK $85,738,000.00
  • ALE $1,532,500,000.00
  • Revenue This Year
  • CYTK $330.96
  • ALE $2.24
  • Revenue Next Year
  • CYTK $73.41
  • ALE $5.63
  • P/E Ratio
  • CYTK N/A
  • ALE $20.24
  • Revenue Growth
  • CYTK 2635.74
  • ALE N/A
  • 52 Week Low
  • CYTK $29.31
  • ALE $63.00
  • 52 Week High
  • CYTK $59.39
  • ALE $66.46
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 49.60
  • ALE 29.80
  • Support Level
  • CYTK $36.89
  • ALE $63.80
  • Resistance Level
  • CYTK $39.92
  • ALE $64.72
  • Average True Range (ATR)
  • CYTK 1.78
  • ALE 0.28
  • MACD
  • CYTK -0.06
  • ALE -0.12
  • Stochastic Oscillator
  • CYTK 54.96
  • ALE 16.75

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About ALE Allete Inc.

ALLETE Inc provides competitively-priced energy in America's Upper Midwest region and invests in transmission infrastructure and other energy-centric businesses. The company has two reportable segments. The first segment is Regulated Operations, which includes the company's regulated utilities, Minnesota Power and SWL&P, as well as its investment in ATC. ATC is a regulated utility based in Wisconsin that owns and maintains electric transmission assets in parts of Wisconsin, Michigan, Minnesota, and Illinois. The second segment is ALLETE Clean Energy, which focuses on developing, acquiring, and operating clean and renewable energy projects.

Share on Social Networks: